Samsung Biologics to acquire Biogen's stake in Samsung Bioepis
Samsung buys Biogen out of biosimilar unit for $2.3B—not the whole Aduhelm headache | Fierce Pharma
Samsung Bioepis seeks to buy Biogen biosimilar unit - KED Global
Biogen shares jump higher on report of potential Samsung acquisition
Samsung Group reportedly in talks to acquire Biogen < Pharma < Article - KBR
Samsung Bioepis ponders acquiring unit from U.S. partner Biogen
Samsung Bioepis conclut un nouvel accord de commercialisation avec Biogen
Biogen/Samsung Takeover - Deal Or No Deal?
Biogen takes on Lucentis, Eylea biosimilars from Samsung joint venture - PMLiVE
Company News | Newsroom | SAMSUNG BIOLOGICS
Biogen to sell equity stake in Samsung Bioepis joint venture for up to $2.3B - Drug Discovery and Development
Biogen and Samsung Bioepis present data for Infliximab and Adalimumab biosimilars - Hub Publishing
Biogen to sell equity stake in Samsung Bioepis joint venture for up to $2.3B - Drug Discovery and Development
Biogen Ups Investment in Biosimilar Drug Maker Samsung Bioepis by $700 Million | BioSpace
Samsung s'associe à Biogen Idec
Biogen and Samsung land FDA approval for biosimilar to blockbuster Roche drug - MedCity News
Le bénéfice de Biogen fait plus que doubler suite à la vente de la participation de Samsung Bioepis -Le 20 juillet 2022 à 13:09 | Zonebourse
Samsung intéressé par le rachat du laboratoire Biogen | La Presse
Samsung in talks to acquire Biogen, per report - The Boston Globe
Samsung Biologics buys out Biogen in biosim venture for US$2.3B | HealthCare Middle East & Africa Magazine
Is Samsung really 'at negotiating table' for Biogen? What we know so far - MM+M
Biogen to sell stake in Samsung Bioepis JV for up to $2.3bn
Samsung in Talks to Buy Alzheimer's Drug Maker Biogen for $42 Billion: Report | Technology News
